现行经股动脉球囊扩张与自膨胀瓣膜TAVR结局比较
该研究基于2015–2018年单中心经股动脉TAVR患者,比较球囊扩张瓣(BE,n=294)与自膨胀瓣(SE,n=269)的30天VARC-2结局及中期预后。经风险校正后,SE组30天缺血性卒中风险更高(6.0% vs 1.4%,P=.015),其余VARC-2指标及中期死亡、再入院、卒中率无显著差异。
要点
- 经风险校正后,自膨胀瓣30天缺血性卒中发生率显著高于球囊扩张瓣。
- 两组30天死亡率、起搏器植入及中度瓣周漏无显著差异。
- 中期死亡、全因再入院及卒中率两组相当,无显著差异。
核心结论
- 两种瓣膜中期结局相当,但自膨胀瓣组短期卒中风险更高。
研究设计与样本
- 单中心回顾性队列研究,纳入2015–2018年经股动脉TAVR患者,BE组294例(52.2%),SE组269例(47.8%)。
主要发现
- BE组男性比例更高(59.9% vs 33.1%,P<.001),体表面积更大(1.9 m2 vs 1.8 m2,P<.001)。
- BE组既往主动脉瓣置换史更少(3.7% vs 10.0%,P=.003),STS预测死亡风险评分更低(4.9% vs 6.7%,P<.001)。
- 经风险校正后,SE组30天缺血性卒中发生率更高(6.0% vs 1.4%,P=.015)。
- 两组30天死亡率(1.7% vs 3.4%,P=.474)、起搏器植入(12.7% vs 15.2%,P=.162)及中度瓣周漏(1.8% vs 3.2%,P=.165)无显著差异。
- 中期死亡(aHR 1.24,P=.269)、全因再入院(aHR 0.92,P=.576)及卒中率(aHR 1.97,P=.061)两组相当。
临床怎么用
- 临床选择瓣膜类型时需权衡短期卒中风险与中期结局,结合患者临床和解剖风险因素个体化决策。
局限性
- 单中心回顾性研究,样本量有限,可能存在选择偏倚和残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcatheter aortic valve replacement (TAVR) continues to gain momentum with current-generation balloon-expandable (BE) Edwards SAPIEN 3 (Edwards Lifesciences, Irvine, CA) and self-expandable (SE) Medtronic Evolut valves (Medtronic, Minneapolis, MN). Safety and efficacy of each device has been studied independently but head-to-head comparisons remain limited. METHODS: The institutional database was used to identify patients undergoing TAVR with BE and SE systems through transfemoral access between 2015 and 2018. Patients with an alternative access were excluded. Multivariable logistic and Cox proportional hazards regression was used to compare baseline risk-adjusted 30-day Valve Academic Research Consortium-2 variables and midterm outcomes, including survival, stroke, and readmission rates. RESULTS: A total of 294 BE (52.2%) and 269 SE (47.8%) valves were implanted. BE cohort was predominantly male (59.9% vs 33.1%, P < .001), with a larger body surface area (1.9 m2 vs 1.8 m2, P < .001), fewer prior aortic valve replacements (3.7% vs 10.0%, P = .003), and a lower Society of Thoracic Surgeons predicted risk of mortality score (4.9% vs 6.7%, P < .001). After risk adjustment, SE patients had a higher propensity of ischemic stroke at 30 days (6.0% vs 1.4%, P = .015) but were comparable in other Valve Academic Research Consortium-2 variables, including mortality (1.7% vs 3.4%, P = .474), pacemaker (12.7% vs 15.2%, P = .162), and moderate paravalvular leak (1.8% vs 3.2%, P = .165). Over the midterm, SE and BE were comparable in mortality (adjusted hazard ratio [aHR], 1.24; P = .269), all-cause readmission (aHR, 0.92; P = .576), and stroke rate (aHR, 1.97; P = .061). CONCLUSIONS: Midterm outcomes of both valve types were comparable despite a higher risk of short-term stroke for the SE cohort. Select patients may benefit from one valve type over another based on clinical and anatomic risk factors.
引用
- Habertheuer A, Gleason TG, Kilic A, et al. Outcomes of Current-Generation Transfemoral Balloon-Expandable Versus Self-Expandable Transcatheter Aortic Valve Replacement. Ann Thorac Surg. 2020. PMID: 33045207. doi:10.1016/j.athoracsur.2020.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。